SwabUp™ Lab Monitoring kit- kit pro monitoring DNA kontaminace hot-spotů v laboratořích molekulární biologie

BLooK- blue light LED transilluminator

FastGene RNA - Kit pro izolaci RNA z tkání a buněčných kultur-superb performance in purifying high quality RNA

logo rbiopharm

RIDA®GENE STI Mycoplasma Panel assay je real-time PCR test pro přímou kvalitativní detekci a diferenciaci Mycoplasma hominis, Mycoplasma genitalium Ureaplasma urealyticum/parvum v humaních vzorcích moče a genitálních stěrů.

logo rbiopharm

Nové real-time PCR testy pro kvalitativní a kvantitativní detekci Akkermansia muciniphila  a  Faecalibacterium prausnitzii DNA ve vzorcích stolice:RIDA®GENE Akkermansia muciniphila & RIDA®GENE Faecalibacterium prausnitzii

Permagen -Magnetické separační stojánky

Permagen -Destičky pro magnetickou separaci 

Cellab® Bioreactor System

Produkty pro stabilizaci NK ve vzorku a stabilizaci/archivaci purifikované DNA/RNA

Nové referenční standardy  pro validaci cfDNA assays

>Prodej předváděcích přístrojů

>Detekce respiračních infekcí-sety RIDA®GENE

>RIDA®GENE Helicobacter pylori 

Real-time PCR assay pro citlivou, specifickou detekci a diferenciaci Helicobacter pylori a její rezistence ke clarithromycinu

>PCRBIO Rapid Extract PCR Kit-rychlá extrakce DNA s vysoce rychlou a specifickou DNA amplifikací. PCR ready DNA v 15 minutách
>genesig qPCR kity pro detekci patogenů
>Primer design produkty
>Clean Circulating DNA Kit
>RIDA®GENE Trichomonas vaginalis

RIDA®GENE Helicobacter pylori

RIDA®GENE Helicobacter pylori Zobrazit větší



Cena: Na vyžádání

Položit dotaz

Více informací

Intended use:

For in vitro diagnostic use. RIDA®GENE Helicobacter pylori is a real-time PCR for the direct, qualitative detection of Helicobacter pylori and its resistance to clarithromycin from human native tissue biopsie material.

The RIDA®GENE Helicobacter pylori real-time PCR is intended for use as an aid in diagnosis of gastric infections caused by Helicobacter pylori.

General Information:

Helicobacter pylori (H. pylori) is a gram-negative rod-shaped bacterium which colonises the human gut. H. Pylori increases the secretion of stomach acid and hence leads to different gastric infections such as Type B Gastritis, gastric ulcers or duodenal ulcers. Worldwide, H. pylori has a prevalence rate of 50%, whereas the infection rate is higher in developing countries compared to developed countries. In Germany, about 33 Mio People are infected with H. pylori of which 10-20% develop ulcers. While the H. pylori strain type 2 lacks the pathogenicity factors cag and VacA, an infection with H. pylori strain type 1 leads to gastroduodenal ulcers and in case of a chronic infection, significantly increases the risk of gastric cancer. To protect itself from gastric acid, H. pylori settles inside the gastric mucosa. Here, H. pylori splits urea by the enzyme urease to increase the pH value in its close surroundings.

Today, H. pylori is detected by microscopy or by using the helicobacter-urease assay from gastric biopsies. Other detection methods are antigen testing or breath tests.

After diagnosis of H. pylori, different treatment measures are possible. Often, the “Triple Therapy” is used which consists of a combination of Amoxicillin, Clarythromycin and a proton pump inhibitor or Metronidazol, Clarythromycin and a proton pump inhibitor. However, increasing clarithromycin resistance lowers the success rate of such a treatment by 30%. Also, other more and more often occurring resistances against antibiotics such as Metronidazol or Levofloxacin (Fluoroquinolon) lead to higher failure in H. pylori eradication therapies.